Alveolar soft part sarcoma (ASPS) is an unusual tumor with highly characteristic histopathology and ultrastructure, controversial histogenesis, and enigmatic clinical behavior. Recent cytogenetic studies have identi®ed a recurrent der(17) due to a non-reciprocal t(X;17)(p11.2;q25) in this sarcoma. To de®ne the interval containing the Xp11.2 break, we ®rst performed FISH on ASPS cases using YAC probes for OATL1 (Xp11.23) and OATL2 (Xp11.21), and cosmid probes from the intervening genomic region. This localized the breakpoint to a 160 kb interval. The prime candidate within this previously fully sequenced region was TFE3, a transcription factor gene known to be fused to translocation partners on 1 and X in some papillary renal cell carcinomas. Southern blotting using a TFE3 genomic probe identi®ed non-germline bands in several ASPS cases, consistent with rearrangement and possible fusion of TFE3 with a gene on 17q25. Ampli®cation of the 5' portion of cDNAs containing the 3' portion of TFE3 in two dierent ASPS cases identi®ed a novel sequence, designated ASPL, fused in-frame to TFE3 exon 4 (type 1 fusion) or exon 3 (type 2 fusion). Reverse transcriptase PCR using a forward primer from ASPL and a TFE3 exon 4 reverse primer detected an ASPL-TFE3 fusion transcript in all ASPS cases (12/12: 9 type 1, 3 type 2), establishing the utility of this assay in the diagnosis of ASPS. Using appropriate primers, the reciprocal fusion transcript, TFE3-ASPL, was detected in only one of 12 cases, consistent with the non-reciprocal nature of the translocation in most cases, and supporting ASPL-TFE3 as its oncogenically signi®cant fusion product. ASPL maps to chromosome 17, is ubiquitously expressed, and matches numerous ESTs (Unigene cluster Hs.84128) but no named genes. The ASPL cDNA open reading frame encodes a predicted protein of 476 amino acids that contains within its carboxy-terminal portion of a UBXlike domain that shows signi®cant similarity to predicted proteins of unknown function in several model organisms. The ASPL-TFE3 fusion replaces the N-terminal portion of TFE3 by the fused ASPL sequences, while retaining the TFE3 DNA-binding domain, implicating transcriptional deregulation in the pathogenesis of this tumor, consistent with the biology of several other translocationassociated sarcomas. Oncogene (2001) 20, 48 ± 57.
Alveolar soft part sarcoma (ASPS) is an unusual tumor with highly characteristic histopathology and ultrastructure, controversial histogenesis, and enigmatic clinical behavior. Recent cytogenetic studies have identi®ed a recurrent der(17) due to a non-reciprocal t(X;17)(p11.2;q25) in this sarcoma. To de®ne the interval containing the Xp11.2 break, we ®rst performed FISH on ASPS cases using YAC probes for OATL1 (Xp11.23) and OATL2 (Xp11.21), and cosmid probes from the intervening genomic region. This localized the breakpoint to a 160 kb interval. The prime candidate within this previously fully sequenced region was TFE3, a transcription factor gene known to be fused to translocation partners on 1 and X in some papillary renal cell carcinomas. Southern blotting using a TFE3 genomic probe identi®ed non-germline bands in several ASPS cases, consistent with rearrangement and possible fusion of TFE3 with a gene on 17q25. Ampli®cation of the 5' portion of cDNAs containing the 3' portion of TFE3 in two dierent ASPS cases identi®ed a novel sequence, designated ASPL, fused in-frame to TFE3 exon 4 (type 1 fusion) or exon 3 (type 2 fusion). Reverse transcriptase PCR using a forward primer from ASPL and a TFE3 exon 4 reverse primer detected an ASPL-TFE3 fusion transcript in all ASPS cases (12/12: 9 type 1, 3 type 2), establishing the utility of this assay in the diagnosis of ASPS. Using appropriate primers, the reciprocal fusion transcript, TFE3-ASPL, was detected in only one of 12 cases, consistent with the non-reciprocal nature of the translocation in most cases, and supporting ASPL-TFE3 as its oncogenically signi®cant fusion product. ASPL maps to chromosome 17, is ubiquitously expressed, and matches numerous ESTs (Unigene cluster Hs.84128) but no named genes. The ASPL cDNA open reading frame encodes a predicted protein of 476 amino acids that contains within its carboxy-terminal portion of a UBXlike domain that shows signi®cant similarity to predicted proteins of unknown function in several model organisms. The ASPL-TFE3 fusion replaces the N-terminal portion of TFE3 by the fused ASPL sequences, while retainingIntroduction Alveolar soft part sarcoma (ASPS) is an unusual tumor with highly characteristic histopathology ( Figure 1 ) and ultrastructure, controversial histogenesis, and enigmatic clinical behavior (Lieberman et al., 1989; Ordonez, 1999) . Most cases of ASPS occur in the second and third decade of life, with a slight female predilection (Lieberman et al., 1989; Ordonez, 1999) . It usually involves the muscle and deep soft tissues of the extremities, but has also been reported in tissues where skeletal muscle is absent. Its cell of origin and biology have remained unclear. Ultrastructural analysis shows secretory-like granules and, in about half of cases, characteristic rectangular or rhomboid crystalline cytoplasmic deposits of unknown composition (Ordonez, 1999) . The treatment is primarily surgical (Lieberman et al., 1989) . Distant metastases are common but often indolent. ASPS appears refractory to all chemotherapy agents tested so far. Although prolonged survival is possible even in patients with metastases, the long term disease-speci®c mortality is high (Lieberman et al., 1989) .
Cytogenetic studies of ASPS prior to 1998 (reviewed in Joyama et al., 1999) described a recurrent add(17)(q25) representing unidenti®ed additional chromosomal material at band 17q25. , Heiman et al. (1998 de®ned this alteration more clearly as a der(17)t(X;17)(p11;q25), and con®rmed its non-reciprocal nature by¯uorescent in situ hybridization (FISH) analysis showing loss of 17q25-qter sequences. Re-evaluation of prior published cases established this as a speci®c recurrent unbalanced translocation in ASPS (Heimann et al., 1998; Joyama et al., 1999) . The localization of the chromosome X breakpoint was subsequently re®ned to Xp11.2 (Joyama et al., 1999) . We show here that this translocation fuses the TFE3 transcription factor gene at Xp11 to a novel gene at 17q25, designated ASPL, in all cases of ASPS tested, implicating transcriptional deregulation in the pathogenesis of this tumor. ASPL is widely expressed in all adult tissues and encodes a predicted protein of unknown function containing a conserved domain possibly related to the ubiquitylation pathway.
Results

Cytogenetic data
Basic clinical data are presented in Table 1 for the 12 ASPS cases with material available for the molecular studies described below. Cases ASPS-6, ASPS-8, and ASPS-9 from Table 1 had informative cytogenetics. ASPS-6 showed 46,XX,der(17)t(X;17)(p11;q25) [6] ( Figure 1 ). The karyotype of ASPS-8 was 45,Y,del(X) (p11),dic(1;14)(p11;p11),+5,der(7)t(1;7)(q11;q36),-13, der(17)t(X;17)(p11;q25),+20,722 [6] (not shown). In the latter case, we could not exclude cytogenetically the presence of the very distal part of 17q on the der(X) because there was no material available for FISH analysis, but the molecular studies reported below support the unbalanced nature of the t(X;17) in this case. In contrast to most other ASPS, there was no net gain of Xp material in ASPS-8. The karyotype in case ASPS-9, 46,XY,der(17)t(X;17)(p11.2;q25) [23] , has been reported previously (Joyama et al., 1999) .
New cytogenetic data were available in one additional previously published case of a thigh tumor in a 21 year old woman (Sciot et al., 1993) , in which the 17q abnormality was originally described as add(17)(q25). The revised karyotype in this case is: 45,XX,del(1)(p11),der(9)t(9;15)(p11;q11), der(17)t(X;17) (p11;q25),722. This case had insucient material for the molecular analysis described below and is not included in Table 1 . Nonetheless, all four cases whose karyotypes are described here contained an unbalanced der(17)t(X;17)(p11;q25), con®rming the consistency of this ®nding in ASPS samples with informative cytogenetics.
FISH analysis of Xp11 breakpoint
To de®ne the interval containing the Xp11.2 rearrangement, we ®rst performed FISH using probes from the OATL1 (Xp11.23) and OATL2 (Xp11.21) regions. A single unstained metaphase cell preparation from case ASPS-6 was available for tricolor FISH studies. Tricolor FISH performed on this case revealed the presence of the OATL1 YAC2 probe on the der(17) chromosome as well as on the two cytogenetically normal X chromosomes in 10 metaphase cells analysed (Figure 2 ). This was con®rmed by bicolor FISH experiments performed on cytologic touch preparations of cases ASPS-1 and ASPS-2 showing three signals for the OATL1 probe and two signals for an alphoid sequence probe speci®c for the X centromere in the vast majority of cells analysed ( Figure 3) . Similar interphase FISH studies using the OATL2 probe showed only two signals, both associated with the X centromere ( Figure 3 ) in ASPS-1 and ASPS-2. These results were consistent with an unbalanced translocation involving a gene between OATL1 and OATL2, a region of approximately 4 Mb. To further narrow the interval we performed FISH on ASPS-1 and ASPS-6 using four cosmids (A02167, U164B6, B1125, I1135) from a previously established 1.1 Mb cosmid contig immediately centromeric to the region covered by OATL1 YAC2 (Schindelhauer et al., 1996) . Bicolor interphase FISH experiments revealed three signals for probes A02167 and U164B6, and two signals for the centromere X-speci®c probe in the vast majority of cells analysed suggesting that, similar to OATL1, these loci were present on the der(17) in addition to the two normal X chromosomes ( Figure 3) . Only two signals for B1125 could be detected, however, indicating that this locus was proximal to the breakpoint on the X chromosome ( Figure 3 ). This allowed us to localize the breakpoint to a 160 kb interval between cosmids U164B6 and B1125. The sequencing of this region is essentially complete (GenBank #AF207550). A previous detailed sequence analysis identi®ed ®ve genes within this region, including UDP-galactose transporter, PIM-2 protooncogene homolog PIM-2H, shaltype potassium channel, JM12 protein, and TFE3 (project p23-3 at http://genome.imb-jena.de/). Among these, TFE3, a transcription factor gene known to be fused to translocation partners on 1 and X in a subset of papillary renal adenocarcinomas (Clark et al., 1997; Sidhar et al., 1996; Weterman et al., 1996) , was considered as the prime candidate. The orientation of TFE3 is with its 3' end telomeric. Further interphase FISH analysis with cosmid I1135, which is located within this 160 kb interval and known by sequence analysis to contain the 3' end of TFE3 (exons 4 ± 8, see GenBank #AF207550), also showed three signals, consistent with its translocation to chromosome 17 ( Figure 3 ).
Southern blot analysis of TFE3
Because TFE3 rearrangements in papillary renal adenocarcinomas most often occur within intron 3 (and less commonly within intron 1) (Clark et al., 1997; Sidhar et al., 1996) , we used the available genomic sequence of TFE3 to design a 728 bp repeat-free probe from intron 3 of TFE3. This TFE intron 3 probe was synthesized by PCR on normal DNA using primers ATCAAGCAGATTCCCTGACAC and TAGGCT- (17)). Equivalent results were obtained with cosmid probe U164B6 (not shown). In contrast, bicolor FISH studies using probes B1125 and OATL2 (in green with CEP X or DXZ1 in red; case ASPS-6) show the normal copy number signals for B1125 and OATL2 adjacent to the X centromeric signals. These results narrow the breakpoint region to the I1135-B1125 interval containing the TFE3 gene (see text)
Novel gene fusion involving TFE3 in a human sarcoma M Ladanyi et al GACATAAAGCAGTGC. Southern blotting using this probe identi®ed rearranged bands in multiple enzyme digests in ASPS-1 ( Figure 4 ) and several other ASPS cases (results not shown). Mapping of the breakpoint in case ASPS-1 narrowed the breakpoint to a 4.4 kb PvuII restriction fragment corresponding essentially to TFE3 intron 3 ( Figure 5 ). The genomic breaks in other ASPS cases were not systematically mapped.
Isolation of a novel fusion transcript containing the 3' end of TFE3
Based on the mapping of the breakpoint to TFE3 intron 3 and on the observation that the functional products of TFE3 rearrangements in papillary renal adenocarcinomas fuse the 3' portion of TFE3 (including at least TFE3 exon 4 and more 3' regions) to 5' portions of the dierent translocation partners (Clark et al., 1997; Sidhar et al., 1996) , we performed a 5' rapid ampli®cation of cDNA ends (RACE) procedure from the 3' portion of TFE3 on total RNA from cases ASPS-1 and ASPS-8. Reverse transcription was primed using a TFE3 exon 5 or exon 7 reverse primer, followed by heminested PCR with nested TFE3 exon 4 reverse primers (see Materials and methods). Among multiple dierent RACE products obtained from both cases, some corresponded to normal TFE3, but in both cases transcripts containing the same novel sequence fused in-frame to TFE3 exon 3 (in ASPS-8) or exon 4 (in ASPS-1) were obtained ( Figure 6 ). This novel sequence, which we designated ASPL (alveolar soft part sarcoma locus), did not match any named genes in GenBank. The full symbol approved by the HUGO Gene Nomenclature Committee is ASPSCR1.
RT ± PCR detection of ASPL-TFE3 fusion transcripts
To con®rm the consistent presence of an ASPL-TFE3 fusion transcript in these tumors, we performed reverse transcriptase PCR (RT ± PCR) using a forward primer from the ASPL sequence (AAAGAAGTC-CAAGTCGGGCCA) and TFE3 exon 4 reverse primer (CGTTTGATGTTGGGCAGCTCA). A sequence-ver- Figure 5 TFE3 genomic map. Restriction sites are derived from published data (Macchi et al., 1995; Sidhar et al., 1996) and from the complete genomic sequence (GenBank #AF207550). For some enzymes only the sites bracketing the region probed are shown. The smallest rearranged restriction fragment detected using the intron 3 probe in case ASPS-1 was the 4.4 kb PvuII fragment. The locations of genomic breaks previously described in papillary renal cancers (see text) are also shown Figure 4 TFE3 genomic rearrangement in case ASPS-1. Southern blot analysis with a TFE3 intron 3 probe shows non-germline bands in both enzyme digests of ASPS-1 genomic DNA, compared to the placental control lanes (PL) Figure 6 Schematic diagram of normal TFE3 and ASPL-TFE3 fusion products (type 1 and type 2) identi®ed by 5' RACE with sequences of fusion junctions. Relative dimensions are approximate. Arrows indicate fusion points in TFE3 and ASPL cDNAs. A minor form of the ASPL transcript contains a 47 nt alternative splice within the 5' untranslated region. UT: untranslated, AD: activation domain, bHLH: basic helix ± loop ± helix DNA-binding domain, LZ: leucine zipper dimerization domain, UBX: UBX domain i®ed ASPL-TFE3 fusion transcript was detected in all ASPS cases (12/12) (Table 1) , including the two cases used for 5' RACE, but was absent in control RNA (K562 leukemia cell line) (Figure 7 ), establishing the potential clinical utility of this RT ± PCR assay in con®rming the diagnosis of ASPS. Two mutually exclusive types of ASPL-TFE3 fusion transcripts were observed, corresponding to the two types of RACE products described above: in three cases, the fusion transcript included TFE3 exon 3 (`type 2') while in the remaining nine cases it did not (`type 1').
RT ± PCR for the reciprocal fusion product, TFE3-ASPL, using TFE3 forward and ASPL reverse primers appropriate to the type of ASPL-TFE3 rearrangement in each case, was positive in ASPS-7 and negative in the other 11 cases, including ASPS-8 (results not shown), consistent with the non-reciprocal nature of this translocation observed cytogenetically in most cases to date.
We also evaluated the expression of the remaining unrearranged alleles of TFE3 and ASPL by RT ± PCR using appropriate TFE3 or ASPL primer pairs¯anking the ASPL-TFE3 fusion point (results not shown). Expression of normal TFE3 was detected in ®ve of seven cases tested. The positive tumors were from four females and one male. Both negative tumors were in males, including case ASPS-8, where cytogenetic data were available and were consistent with this ®nding (see above). Normal ASPL transcripts were detected in ®ve of ®ve cases tested. Although these tumor samples typically contain 490% tumor cells, the possibility that the normal transcripts detected in this PCR-based analysis were derived from non-neoplastic tumor stromal cells cannot be completely excluded.
Isolation of the full length ASPL cDNA
Separate 5' and 3' portions of the partial ASPL sequence obtained from the TFE3 5' RACE (see above) matched two non-overlapping human expressed sequence tags (ESTs) (GenBank #AA489553 and #AA056378), respectively from IMAGE clones 843309 (HeLa) and 509449 (normal colon). These two IMAGE clones belong to the anonymous Unigene cluster Hs.84128, composed of ESTs from a wide variety of source tissues. We ®rst extended the ASPL sequence by a 5' and 3' walk in the ESTs of this human Unigene cluster. To complete the 5' sequence, we performed 5' RACE using nested reverse primers, on double-strand adaptor-ligated HeLa cDNA (Marathon cDNA, Clontech). The sequence of the 3' end, available in multiple ESTs, was also con®rmed by 3' RACE on the tailed HeLa cDNA. The assembled complete sequence of the normal ASPL cDNA was con®rmed by resequencing.
The 1872 nucleotide (nt) ASPL cDNA (Figure 8 ) lacks signi®cant homology to previously characterized human genes. A search of the ASPL cDNA sequence against the draft human genome sequence showed a near perfect head-to-head match of its 5' end with the 5' end of BAC clone RP11-489C9 recently assigned to 17q25, approximately 1.7 Mb from the telomere (GenBank #AC069004). The only sequence discrepancy was a silent dierence, CCA vs CCG, at codon 45, presumably representing a polymorphism. The match with the portion of the ASPL genomic sequence allowed us to de®ne the ®rst four exon boundaries within the ASPL cDNA (Figure 8 ).
We also identi®ed major and minor splice forms of the ASPL transcript which dier respectively by the absence or presence of a 47 nt segment from exon 2, which encodes part of the 5' untranslated portion of ASPL (Figures 6 and 8 ). This 47 nt segment seem to represent a`cryptic intron' (Bruce et al., 1999; Haselo et al., 1997 ), yet it lacks canonical exon splice junctions. That both splice forms are present in cDNA rather than deriving from contaminating genomic DNA was con®rmed by RT ± PCR assays spanning exon boundaries. Speci®cally, the expression of the minor splice form containing the additional 47 bp portion of exon 2 was detected by PCR using a reverse primer from this region (GCTTTTCCAAGTGA-GAGCCAG) with an exon 1 forward primer (GGGTCACGTGAGCGGAAAATG) in cDNA from HeLa cells and two ASPS cases (ASPS-7 and ASPS-8) (results not shown). However, PCR primers bracketing this alternatively spliced 47 bp fragment, GCTTCAGGTTCTGGAGGACAC (straddling the boundary of exons 1 and 2) and ATCCCTCGTGTA-CACGCAGACT (from exon 5), produced only the 360 bp fragment expected from transcripts lacking the 47 bp portion, suggesting that this is the major splice form of ASPL, at least in the cDNAs tested (HeLa, K562, ASPS-2, ASPS-7).
Sequence analysis of ASPL predicted protein
The ASPL cDNA open reading frame encodes a predicted protein of 476 amino acids that shows signi®cant identity (29 ± 33%) and similarity (46 ± 51%) within its carboxy-terminal portion (approximate residues 263 ± 385) to predicted proteins of unknown function in Saccharomyces cerevisiae (YMV7 product; SwissProt #P54730), Arabidopsis thaliana (GenBank #AAD12706), Drosophila melanogaster (CG5469 product; GenBank #AAF47656), and Caenorhabditis elegans (B0024.10 and H06H21.6 products; GenBank #T18645 and #AAC69496) (Figure 9 ). By Pro®leScan analsyis, this carboxy-terminal portion of ASPL Figure 7 Detection of ASPL-TFE3 in all ASPS cases by RT ± PCR. Agarose gel showing speci®c ASPL-TFE3 products in 9/9 ASPS cases, but not in negative controls (K562 and reaction lacking RNA). Type 2 products dier by the inclusion of TFE3 exon 3 in the chimeric transcript (see Figure 6 and text) 
Chromosomal assignment and expression analysis of ASPL
We identi®ed a reverse primer from ASPL (CTCCTGCTCCTGCTGGGGATC) which appeared to be located on the same exon as the forward primer AAAGAAGTCCAAGTCGGGCCA used for the ASPL-TFE3 RT ± PCR. This was evidenced by the ampli®cation of a product of the expected size (80 bp) from normal genomic DNA. Using this primer pair, PCR analysis of monochromosomal somatic cell hybrid DNAs (Coriell Institute, Camden, NJ, USA) con®rmed that ASPL maps to chromosome 17 (results not shown).
To assess the normal expression pattern of native ASPL, we hybridized Northern blots of various adult and embryonal human tissues (Clontech, Palo Alto, CA, USA) with an ASPL partial cDNA probe. The predominant normal ASPL transcript is about 1.9 kb in size and is detected in all tissues tested (Figure 10 ). When normalized to b-actin transcript level (not shown), the highest ASPL expression was seen in heart, skeletal muscle, pancreas (Figure 10 ), and testis (not shown). Slightly lower expression was seen in the remaining tissues examined [kidney, liver, lung, placenta, brain (Figure 10) , leukocytes, colon, small bowel, ovary, prostate, thymus, spleen (not shown)]. Expression of ASPL in fetal tissues, including kidney, liver, lung, brain, and heart, appeared notably lower than in adult tissues (not shown). In a Northern blot panel of human cancer cell lines (Clontech), ASPL was expressed in all cell lines, with somewhat higher levels in K562, A549, G361, and SW480, and lower levels in Raji, MOLT4, HeLa, and HL60 (Figure 10 ). The ubiquitous expression of ASPL by Northern blot analysis is consistent with the wide variety of source The 47 nt alternatively spliced portion of exon 2 is shown in lowercase (see text). There are two potential in-frame initiation codons (underlined), but the ®rst initiation codon is phylogenetically more conserved (analysis not shown). The second one presents a more favorable Kozak consensus context for translation initiation (Kozak, 1991) . A silent mismatch with the genomic sequence from BAC RP11-498C9 at codon 45 is shown in italic. The fusion point with TFE3 is shown by the arrow. The portion of the ASPL putative protein showing a signi®cant match to the UBX domain pro®le is in boldface. The polyadenylation site is underlined. GenBank accession numbers for ASPL are AF324219 and AF324220 Oncogene Novel gene fusion involving TFE3 in a human sarcoma M Ladanyi et al tissues of ASPL ETSs within Unigene cluster Hs.84128.
Discussion
Since the recognition of ASPS as a distinct clinicopathologic entity in 1952 (Christopherson et al., 1952) , its cell of origin and biology have remained unclear. Its typical presentation is as an intra-or perimuscular thigh mass in a young woman, an observation con®rmed in the present group of patients (Table 1) , but it has also been reported in tissues where skeletal muscle is absent, such as stomach, retroperitoneum, breast, and female genital tract, among others. Its proposed origin from skeletal muscle precursor cells has been the subject of several studies and considerable controversy (Gomez et al., 1999; Rosai et al., 1991; Tallini et al., 1994; Wang et al., 1996) . In some sarcomas (e.g. alveolar rhabdomysarcoma and myxoid liposarcoma), speci®c translocations subvert transcription factors involved the normal dierentiation of their respective cell types (e.g. PAX3 and CHOP). In contrast, in ASPS neither translocation partner shows a tissue-speci®c expression pattern, and therefore the ASPL-TFE3 fusion so far does not provide any additional clues to the cell of origin or dierentiation program of this enigmatic tumor. The consistent detection of the ASPL-TFE3 fusion in ASPS identi®es it as a marker of potential clinical utility to add to the growing list of translocation-based molecular diagnostic markers in sarcomas (Ladanyi and Bridge, 2000) .
TFE3, along with TFEB, TFEC, and MITF, forms the microphthalmia-TFE (MiT) subfamily of basic helix ± loop ± helix leucine zipper (bHLH-LZ) transcription factors (Hemesath et al., 1994; Rehli et al., 1999) . TFE3 was initially identi®ed through its binding to the immunoglobulin heavy chain gene enhancer mE3 motif (Beckmann et al., 1990) , where it forms part of a complex that includes tissue-restricted ETS domain transcription factors (Tian et al., 1999) . The ubiquitous expression of TFE3 suggests a wider physiologic role (Beckmann et al., 1990) . Indeed, TFE3 has also recently been implicated in cell type-speci®c expression of target genes in the melanocytic and peripheral neuroendocrine lineages (Verastegui et al., 2000; Wong et al., 1995) . TFE3 also appears to cooperate with Smad proteins in at least one TGF-beta-activated signal transduction pathway, the one leading to activation of the plasminogen activator inhibitor-1 gene (Hua et al., 1998 (Hua et al., , 1999 . Thus, TFE3, although broadly expressed, may achieve functional speci®city through interactions with more tightly regulated proteins.
As stated above, TFE3 is rearranged within its ®rst or third intron by speci®c reciprocal translocations involving Xp11.2 in a subset of papillary renal adenocarcinomas (Sidhar et al., 1996; Weterman et al., 1996) . In most cases, the translocation partner is a novel gene designated PRCC at 1q21.2 and the PRCC-TFE3 fusion transcript includes all but exon 1 of TFE3, thereby containing the entire coding region of TFE3 (Sidhar et al., 1996) . In some papillary renal adenocarcinomas, TFE3 fuses instead with the splicing factor genes, PSF at 1p34 or NonO at Xq12 (Clark et al., 1997) . ASPL shows no sequence similarities to PRCC, PSF, or NonO. The PSF-TFE3 and NonO-TFE3 fusions exclude the ®rst three exons of TFE3, thereby replacing its activation domain by the fused sequences, while retaining the TFE3 bHLH-LZ DNAbinding domain, encoded by exons 5 to 7. Thus, they are structurally similar to the ASPL-TFE3 type 1 fusion, although ASPL shows no sequence homology to PRCC, PSF, or NonO. In the predicted ASPL-TFE3 fusion protein, the amino terminal 234 amino acids are fused with the carboxy terminal 280 or 315 amino acids of TFE3 in the type 1 and type 2 fusions, Predicted proteins from Arabidopsis thaliana (At2g01650 product; GenBank #AAD12706), Drosophila melanogaster (CG5469 product; GenBank #AAF57656), and Saccharomyces cerevisiae (YMV7 product; SwissProt #P54730), are aligned with a portion of ASPL. This portion of ASPL shows signi®cant matches to the pro®les of the UBX domain (PF00789) and the UX domain (PS50033) using Pro®leScan (Nscores of 9.989 and 12.443, respectively), in the portions indicated for each. Key: *=single, fully conserved residue; :=conservation of strong groups, .=conservation of weak groups Figure 10 Northern blot analysis of expression of ASPL in normal adult human tissues and human cancer cell lines. Even loading of lanes was con®rmed by rehybridization with a b-actin probe (not shown). HL60: promyelocytic leukemia, HeLa: cervical carcinoma, K562: chronic myelogenous leukemia, MOLT4: lymphoblastic leukemia, Raji: Burkitt's lymphoma, SW480: colorectal adenocarcinoma, A549: lung carcinoma, G361: melanoma respectively. We mapped the TFE3 genomic break in one case with a type 1 fusion and it was localized to intron 3, as would be expected. We did not map the genomic break in any case with the type 2 fusion. These could aect intron 2 which is very small (81 bp) or may occur further upstream and produce a fusion transcript involving TFE3 exon 3 by splicing out of more upstream exons.
TFE3 contains a nuclear localization signal located between the basic domain and the ®rst helix (Weterman et al., 2000) , a region retained within the predicted ASPL-TFE3 fusion protein. In transactivation assays using a TFE3-speci®c reporter system, PRCC-TFE3 is a stronger activator than TFE3 (Weterman et al., 2000) . These considerations, along with the apparently constitutive activity of the ASPL promoter, suggest that in ASPS, ASPL ± TFE3 may similarly exert its pathogenic eect through transcriptional deregulation, consistent with the biology of several other translocation-associated sarcomas. Whether this deregulation takes the form of a gain-of-function or a dominant negative remains to be determined. By sequence analysis, ASPL lacks any obvious activation domain and ASPL ± TFE3 type 1 fusions also lack the TFE3 activation domain, which has been mapped to exon 3. Thus, the ASPL ± TFE3 type 1 fusion product could function as a dominant negative, akin to TFE3 splice forms lacking exon 3 (Roman et al., 1991) , through homo-di-or tetra-merization mediated by its bHLH-LZ domain (Artandi et al., 1994) . MiT family members are known to heterodimerize (Hemesath et al., 1994) , and this could extend the transcriptional deregulation eected by ASPL ± TFE3 beyond the targets of normal TFE3.
ASPL, along with similar predicted proteins in several model organisms, may de®ne a new UBX domain subfamily related to the yeast YMV7 product (Figure 9 ). The UBX domain has not yet been de®ned in terms of function or tertiary structure. Its identi®ca-tion in some proteins [human predicted proteins Y33K (Swiss Prot #Q04323) and HUMORF (GenBank #M68864)] also containing the ubiquitin-regulatory UBA domain (Hofmann and Bucher, 1996) suggests that it may be somehow related to the ubiquitylation pathway, a role that remains to be proven experimentally. Its co-occurrence with the UBA domain in selected proteins led to its designation as a UBAassociated domain, but most proteins containing UBX domains actually lack a UBA domain. Named proteins containing UBX domains include human FAF1 and REP8, and yeast shp1.
Most translocations producing fusion genes commonly appear cytogenetically reciprocal, with no net gain or loss of genetic material, even though only one of two resulting chimeric genes is pathogenetically signi®cant. Indeed, few if any such translocations are consistently unbalanced. An unusual feature of the t(X;17) in ASPS is its consistently non-reciprocal nature, observed cytogenetically in all cases to date (Heimann et al., 1998; Joyama et al., 1999) , and supported by the absence of a reciprocal TFE3-ASPL fusion transcript in 11/12 cases tested in the present series. Incidentally, the presence of a normal X in some males with the t(X;17) (e.g. case ASPS-9 described above and in Joyama et al. (1999) ) suggests that the translocation occurs in the G2 phase of the cell cycle, at least in these cases. Interestingly, in contrast to the unbalanced t(X;17)(p11.2;q11) of soft tissue ASPS, a balanced t(X;17)(p11.2;q11) has been reported in rare tumors described as pediatric renal adenocarcinomas (Heimann et al., 1998; Hernandez-Marti et al., 1995; Tomlinson et al., 1991) . We now ®nd that all such cases tested display an ASPL-TFE3 fusion transcript and may be morphologically and biologically related to ASPS (P Argani, M Ladanyi, unpublished observations).
Because of the unbalanced nature of the t(X;17), almost all ASPS harbor allelic loss of 17q25 sequences telomeric to ASPL and most show a gain of Xp sequences telomeric to TFE3 (representing most of the short arm). Indeed, gain of Xp11-pter has been detected by comparative genomic hybridization in a case of ASPS (Kiuru-Kehlefelt et al., 1998) . The non-reciprocal structure of the ASPL-TFE3 rearrangement suggests a special biology in ASPS combining fusion protein formation with pathogenetic losses and/or gains of other as yet uncharacterized genes, akin to ETV6-AML1 formation and ETV6 loss in pediatric acute lymphoblastic leukemias (Golub et al., 1997) . The possible additional role of these recurrent translocation-associated genetic imbalances in the biology of this sarcoma remains to be elucidated.
Materials and methods
Tumor samples
Frozen tissue, available in 12 cases histologically diagnosed as ASPS (Table 1) , was used for nucleic acid extraction in all cases and touch preparations (for FISH) in some cases. The basic patient data in the 12 cases which had sucient material for studies of the ASPL-TFE3 fusion are provided in Table 1 . Positivity for ASPL-TFE3 was not a criterion for inclusion in the study group.
Cytogenetic analysis
Cytogenetic analysis was performed on sterile representative samples of cases ASPS-6 and ASPS-7 using standard culture and harvesting procedures. Brie¯y, the tissue was disaggregated mechanically and enzymatically, then cultured in RPMI 1640 media supplemented with 20% fetal bovine serum and 1% penicillin/streptomycin-L-glutamine (Irvine Scienti®c, Santa Ana, CA, USA) for 3 ± 5 days. Two to four hours prior to harvest, cells were exposed to colcemid (0.02 mg/ml). Following hypotonic treatment (0.074 M KCl for 30 min for asks and 0.8% Na citrate for 25 min for coverslips), the preparations were ®xed three times with methanol:glacial acetic acid (3 : 1). Metaphase cells were banded with Giemsa trypsin. The karyotypes were expressed according to the International System for Human Cytogenetic Nomenclature 1995.
Fluorescence in situ hybridization
Six probes localized to subregions of Xp11.2 (OATL1 YAC2, cosmid A02167, cosmid U164B6, cosmid I1135, cosmid B1125, and OATL2) were used. The OATL1 and OATL2 probes were kindly provided by A Geurts van Kessel. The relative locations of these probes are illustrated in Figure 3 . One mg of each DNA probe was directly labeled with SpectrumOrange or SpectrumGreen using a nick translation kit (Vysis, Downer's Grove, IL, USA) according to the manufacturer's instructions. The labeled DNA was puri®ed through a Sephadex G50 column and precipitated in the presence of sonicated herring sperm DNA (15 mg). The labeled DNA was then co-precipitated for annealing purposes with 2 mg Cot-1 DNA (sonicated total human DNA).
Bicolor FISH studies were performed with probe mixtures of the directly labeled YAC or cosmid clone probes listed in Figure 3 and directly or indirectly labeled centromere X-speci®c alphoid sequence (CEP X (Vysis) or DXZ1 (Ventana Medical Systems, Tucson, AZ, USA)) on cytologic touch preparations of two of the ASPS specimens (ASPS-1 and ASPS-6). Tricolor FISH studies utilizing a SpectrumOrange labeled CEP X probe, a SpectrumAqua labeled CEP 17 probe (CEP X and CEP 17 probes, Vysis Inc., Downer's Grove, IL, USA) and a SpectrumGreen labeled OATL1 YAC2 probe. The metaphase or interphase slides to be hybridized were pretreated with RNase A (100 mg ml 71 in 26SSC at 378C for 1 h) and eventually, porcine pepsin (0.01% (w/v) in 0.01 M hydrochlorine acid, 5 min at 378C), followed by formaldehyde post-®xation (1% (v/v) in MgCl 2 phosphate-buered saline (PBS) for 10 min at room temperature). Subsequently, the slides were denatured in 70% formamide, 26SSC, pH 7.0, at 738C for 2 ± 3 min and placed immediately into cold 70% EtOH, followed by a cold ethanol series of 80, 90 and 100%. The slides were then placed on a slidewarmer for 10 min at 458C prior to hybridization. The probes tested were denatured at 758C for 5 min, chilled on ice and incubated at 378C for 10 min. The cells and probes were sealed under an 18618 mm coverslip and incubated for 16 ± 18 h at 378C in a humidity chamber.
Images were prepared utilizing the Applied Image Analysis System (Applied Imaging, Pittsburgh, PA, USA). The number of hybridization signals for each probe was assessed in a minimum of 200 interphase nuclei with strong and well-delineated signals by two dierent individuals. As negative controls, normal peripheral-blood lymphocytes were simultaneously hybridized with these probes.
Southern and Northern blot analysis
For Southern blotting, genomic DNA was isolated by standard organic methods. Aliquots (10 mg) of DNA were digested with speci®c restriction enzymes, separated on 0.8% agarose gels and transferred onto nylon membranes, and subjected to ultraviolet cross-linking for 5 min. Southern blots and commercially obtained Northern blots (Clontech, Palo Alto, CA, USA) were prehybridized for at least 1 h and subsequently hybridized in Hybrisol (Intergen, Purchase, NY, USA) with probes radiolabeled to a high speci®c activity by the random primer technique. The ®lters were washed at high stringency and imaged using X-ray ®lm or a phosphorimager (BioRad, Hercules, CA, USA).
Isolation of ASPL-TFE3 and ASPL cDNAs
We used the 5' rapid ampli®cation of cDNA ends (RACE) system from GIBCO BRL (Rockville, MD, USA). Brie¯y, after annealing of a TFE3-speci®c reverse primer from exon 5 (CAAAAGGGCCTTTGCCTCGGTC) or exon 7 (CAG-GATGGTGCCCTTGTT), the RNA was copied into cDNA with Superscript II reverse transcriptase. The RNA was then degraded with RNase and the cDNA was puri®ed by GlassMAX Spin Cartridge (GIBCO BRL). The puri®ed cDNA was then tailed with dCTP using TdT. The dCtailed cDNA was then subjected to PCR ampli®cation using the manufacturer's Abridged Anchor Primer as forward primer and a nested TFE3-speci®c reverse primer from exon 4 (CGTTTGATGTTGGGCAGCTCA). For the ®rst PCR step, either AmpliTaq (Perkin Elmer, Norwalk, CT, USA) or HotStarTaq (Qiagen, Valencia, CA, USA) were used. Five ml of 100-fold dilution of the ®rst PCR products was then reampli®ed using AmpliTaq in a second PCR with heminested primers, consisting of the manufacturer's Abridged Universal Anchor Primer, and another TFE3 exon 4 reverse primer (GCAGGAGTTGCTGA-CAGTGAT). Discrete product bands observed on the agarose gel were excised and subjected to direct sequencing on an automated sequencer using the latter primer or a further nested primer from TFE3 exon 4, (CCTTGAC-TACTGTACACATC).
To isolate the 5' end and con®rm the 3' end of the normal ASPL cDNA, we used 5' and 3' tailed HeLa cDNa (Marathon cDNA, Clontech). Appropriate reverse (CAAA-GAACTCAATCATGGCAG) and forward (AAAGAAGTC-CAAGTCGGGCCA) primers from ASPL were used respectively for the 5' and 3' RACE, in combination with the supplied AP1 anchor primer for the tailed ends.
RT ± PCR for ASPL-TFE3
First, reverse transcription was performed for 30 min at 428C on 1 mg of RNA using 106 buer II, 25 mM MgCl 2 , 50 mM random hexamers, 10 mM dNTP, 40 U/ml RNAse inhibitor, 200 U/ml reverse transcriptase and DEPC-treated H 2 O for a ®nal volume of 20 ml. A negative control (10 ml of DEPC-water) was included at this stage. The reverse transcriptase was inactivated at 998C for 5 min. Eighty ml of master mix (water, 106 buer II, MgCl 2 for a ®nal concentration of 1.5 mM, 15 pMol of each primer (see Results for primer sequences), 5 U/ml of AmpliTaq DNA Polymerase (Perkin Elmer) were added to the tube). PCR consisted of 35 cycles of 958C for 1 min, 608C for 1 min, 728C for 1 min, ®nal extension of 728C for 10 min. The PCR products were electrophoresed in 2% NuSieve agarose gel (FMC Bioproducts, Rockland, ME, USA) and visualized by ethidium bromide staining.
To detect the presence of an ASPL-TFE3 fusion transcript, we performed RT ± PCR using a forward primer from ASPL (AAAGAAGTCCAAGTCGGGCCA) and a TFE3 exon 4 reverse primer (CGTTTGATGTTGGGCAGCTCA), as previously described. RT ± PCR for the reciprocal fusion product, TFE3-ASPL, was performed using an ASPL reverse primer (CACCGTCAGCTCAAAGAACTC) and a TFE3 forward primer appropriate to the type of ASPL-TFE3 rearrangement in each case: for cases with a type 1 ASPL-TFE3 fusion, a TFE3 exon 3 forward primer (TTGAT-GATGTCATTGATGAGATC), and in cases with a type 2 ASPL-TFE3 fusion, a more upstream TFE3 primer (GCTCAAAAGCCAACCCTTAC).
